SEO for DTC pharma is search optimisation for branded and unbranded pharmaceutical content, built to survive MLR review and FDA fair-balance requirements. The highest-volume commercial demand in the category is affordability: patient assistance programmes, savings cards and copay support carry tens of thousands of monthly searches, are largely brand-owned territory, and are the one place a pharmaceutical brand can rank commercially without stepping outside its label.
- 17
- exits, all built on organic search
- $150M
- revenue generated for clients
- 35+
- team members worldwide
- 100%
- hands-off, fully managed
What this looks like when it works
Every figure below is from live client work. Brand names are withheld at client request; we walk through the accounts, dashboards and timelines live on the call.
All case studiesTop 3
for "buy mounjaro" in the UK
Top 3 for the most contested term in UK weight loss
$550k
organic revenue in 2.5 months
A research-use-only peptide brand, $550k from organic
19.32x
ROSI in 90 days
An organic revenue engine built in a single quarter
01
The demand is affordability, and it is enormous
Search the category properly and the same shape appears on every drug: the branded term is dominated by the manufacturer and the medical publishers, and the live, winnable, high-intent demand sits one step later, on the question of how to pay for it.
| Keyword | Volume | Difficulty | CPC |
|---|---|---|---|
| eliquis patient assistance program | 4,400 | 51 | $1.80 |
| novo nordisk patient assistance program | 4,200 | 31 | $1.30 |
| patient assistance program | 3,400 | 61 | $3.00 |
| ozempic patient assistance program | 3,000 | 54 | $4.00 |
| mounjaro patient assistance program | 2,900 | 0 | $2.50 |
| prescription savings card | 2,700 | 67 | $1.00 |
| zepbound patient assistance program | 2,100 | 66 | $1.80 |
"mounjaro patient assistance program" carries 2,900 searches a month at difficulty 0.\n\nDifficulty zero, on a term about a drug with a multi-billion dollar run rate, at a $2.50 CPC. That is not an obscure long tail, it is one of the most-searched questions about one of the most-prescribed drugs in the country, and the market is not answering it.\n\nAcross these seven terms alone there are more than 22,000 monthly searches, all from people who have already been prescribed something or are about to be. There is no awareness work to do with this audience. They know the drug, they know the doctor, and they are trying to work out whether they can afford it.\n\nThis is the single most under-served demand pool we have measured in any healthcare category, and it belongs to the manufacturer more naturally than to anyone else, because the manufacturer runs the programme.
02
Branded, unbranded, and the line MLR actually draws
Pharmaceutical search splits into two content estates with different rules, and most teams conflate them.\n\nBranded content names the product and therefore carries the full weight of fair balance: indication, important safety information, and a link to prescribing information, present and prominent. This is not a burden to design around, it is a constraint that shapes the page, and pages built for it from the start read better than pages that had ISI stapled on at the end.\n\nUnbranded disease-state content does not name the product and can therefore rank for the conditions, symptoms and treatment-option queries that dwarf branded volume. The rule that matters is that unbranded content cannot become a de facto product advertisement. If the page is engineered so the only possible conclusion is your drug, you have written branded content without the safety information.\n\nAffordability content is the third estate and the most useful one. A patient assistance page is branded, but it is answering a question the patient has already asked about a drug they have already been prescribed, which makes fair balance straightforward rather than awkward.\n\nEvery page in all three estates goes through review before it is live. That is not a slowdown we tolerate, it is the reason the content survives.
03
Building an SEO programme that survives MLR
The reason pharmaceutical content programmes stall is almost never strategy. It is throughput. A page takes eleven weeks through medical, legal and regulatory review, the keyword landscape has moved by the time it publishes, and the team concludes that SEO does not work in pharma.\n\nWhat actually failed was the workflow. Three changes fix it.\n\nThe first is pre-approved modular components. ISI blocks, indication statements, safety summaries and reference formats reviewed once and reused, so each new page presents reviewers with genuinely new copy rather than the same boilerplate to re-read.\n\nThe second is submitting in batches by template rather than page by page. Reviewers assess a page type and its rules once, and subsequent pages of that type move at a fraction of the cost.\n\nThe third is writing to the constraint. Copy drafted by writers who know what will not clear comes back with comments rather than rejections, and the difference across a year of publishing is measured in dozens of pages.\n\nNone of this is a way around review. It is a way to make review fast enough that a content programme can actually exist inside it.
04
Prescriber locators and the last mile
The final piece of pharmaceutical search is the one closest to a conversion the brand can actually measure: helping a patient who wants the drug find someone who will prescribe it.\n\nPrescriber locator pages, telehealth partner pages and "how to talk to your doctor about" content all sit at the end of the journey, and they are where the manufacturer's site earns its keep. The person searching has been through awareness, has decided, and is looking for the mechanism.\n\nThese pages also carry a structural advantage. Location-modified prescriber queries are numerous, individually low volume, and almost entirely unclaimed, which makes them a compounding asset rather than a single ranking.\n\nThe same is true of the assistance journey. A savings page that ends in an eligibility check and an enrolment route is a conversion path, not a leaflet, and treating it as one changes what the whole programme is worth.
Here is what happens if nothing changes
01
Difficulty 0 on 2,900 searches will not last
The assistance terms are open because nobody has built for them. One competent programme closes that window.
02
Aggregators are answering for your drug
Every affordability question you do not answer is answered by a coupon site with no obligation to be accurate.
03
MLR throughput compounds either way
Teams that fix the workflow publish for years. Teams that do not publish four pages and stop.
04
Assistants cite whoever explained the programme
And on your own patient assistance programme, that should not be a third party.
When I am asked if I know of anyone in the SEO space, without hesitation I point them to DTC SEO. They truly understand the power of authority content, onsite metrics, and strategic backlinking and has the network to put it into play.
Links we have landed for clients
- Forbes
- TIME
- Cosmopolitan
- Men's Health
- Inc
- Martha Stewart
- Time Out
- Apartment Therapy
- mindbodygreen
- well+good
- OK!
- Best
MLR is the constraint, not the obstacle
Tell us your review capacity and we will show you the publishing plan that fits inside it.
Step 1 of 5
What is your website?
Your domain is enough.
- Rated on Trustpilot
- Part of DTC SEO Agency
- Award-winning SEO agency
- $150M revenue generated for clients
- We built and run our own telehealth brand
What we deploy for DTC pharma brands
AI Search and GEO
Getting cited inside ChatGPT, Perplexity and AI Overviews, and an honest account of what that is currently worth.
Doctor-Reviewed Content
Expert writers produce it. A licensed physician signs off on clinical accuracy before it goes live. In YMYL categories that step is not optional.
Digital PR
We connect your business to a credentialed expert and place their commentary in publications with real editorial standards. Their credibility becomes yours.
Link Building
Health publishers vet harder and charge more, which is why most agencies avoid the category and why links remain the largest ranking lever in it.
Technical SEO
Regulated catalogues accumulate structural problems general ecommerce sites never encounter. Most of the fix is consolidation rather than creation.
Programmatic SEO
Location and variant pages at scale, built as data rather than as templates, so they inform rather than duplicate.
Closely related categories